Le Lézard
Classified in: Health
Subjects: TRI, FDA

Mezzion Pharma announces positive results from the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, in adolescents with single ventricle heart disease who have undergone the Fontan procedure

SEOUL, Korea, July 30, 2019 /PRNewswire/ -- Mezzion Pharma Co. Ltd. today announced that top line data from the Phase 3 FUEL trial, which was designed to evaluate the safety and efficacy of udenafil for the treatment of certain adolescents with congenital single ventricle heart disease (SVHD), had positive results for key parameters. Although Mezzion is restricted in providing specific data results at the present time due to contractual obligation, the Company is looking forward to publication of the full results in a peer reviewed journal and the presentation of the clinical trial data at a major scientific meeting later this year.

The FUEL Trial is a study in 400 male and female adolescents with a single functional ventricle who had previously undergone Fontan surgical palliation. Study participants were drawn from a total of 30 Pediatric Heart Network http://www.pediatricheartnetwork.org/ (PHN) and auxiliary sites throughout the U.S., Canada, and Korea. The PHN is funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

In view of these results from the FUEL trial and the safety data collected about the drug candidate over other clinical studies, Mezzion Pharma intends to submit a New Drug Application to the U.S. Food and Drug Administration to seek approval for the use of udenafil to treat adolescents with SVHD who have undergone Fontan palliation.

In addition to this FUEL trial, Mezzion continues forward in its clinical efforts with the FALD study, also conducted under the auspices of the PHN, which is measuring the ability of udenafil to impact the effects of Fontan Associated Liver Disease.  

Mezzion Pharma Co. Ltd.

Mezzion Pharma is a publicly-listed biotech company in Korea focusing on the development of new drugs.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.


Mr. YT Song
Tel: +82 2 560 8011
Email: ytsong@mezzion.co.kr

SOURCE Mezzion Pharma Co. Ltd.

These press releases may also interest you

at 17:19
Qualigen Therapeutics, Inc. ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $8,000,000 of (i) 1,200,000 Common Shares, (ii) 780,198...

at 17:15
The "Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity" report...

at 17:05
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal Phase 1/2 study results demonstrated...

at 17:00
ResearchAndMarkets.com published a new article on the mental health industry "Mental Health Practitioners Move to Online Services as a Result of COVID-19" High unemployment, social isolation as well as coronavirus related fears could contribute to...

at 17:00
Digital health company Carrot Inc. today announced that AllegisNL Capital invested in its latest round of financing to accelerate commercialization of its Pivot tobacco cessation program. AllegisNL is backed by one of the largest life insurance...

at 17:00
Mindbody, the leading technology platform for the wellness industry, today announced that the company's co-founder Rick Stollmeyer is transitioning from the role of chief executive officer to executive chair and that the Mindbody Board of Directors...

News published on 30 july 2019 at 19:42 and distributed by: